CompletedNot Applicable

Predict MDE Outcomes After MST

China45 participantsStarted 2020-07-20

Plain-language summary

This trial attempts to explore the treatment outcome of magnetic seizure therapy (MST) for major depressive episode. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy (ECT).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. DSM-5 diagnosis of major depressive episode;
✓. convulsive therapy clinically indicated, such as severe psychomotor excitement or retardation, attempts of suicide, being highly aggressive, pharmacotherapy intolerance, and ineffectiveness of antipsychotics;
✓. the HAMD-17 ≥ 24;
✓. informed consent in written form.

Exclusion criteria

✕. primary diagnosis of other mental disorders;
✕. severe physical diseases, such as stroke, heart failure, liver failure, neoplasm, and immune deficiency;
✕. present with a laboratory abnormality that could impact on efficacy of treatments or safety of participants;
✕. failure to respond to an adequate trial of ECT lifetime;
✕. are pregnant or intend to get pregnant during the study;
✕. Unremovable metal implants.
✕. other conditions that investigators consider to be inappropriate to participate in this trial.

What they're measuring

changes in the 17-item Hamilton Depression Rating Scale (HAMD-17)

Timeframe: At baseline and 4-week follow-up

Trial details

NCT IDNCT03841019

SponsorShanghai Mental Health Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-15

View on ClinicalTrials.gov More Major Depressive Episode trials